Letter re: Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting: Are real-world data sufficient to draw a comparison between CDK4/6 inhibitors?
作者信息
Sertesen Camoz E, Onur I D, Yildiz F
机构信息
Department of Medical Oncology, University of Health Science, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey.
Department of Medical Oncology, University of Health Science, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey.
出版信息
ESMO Open. 2025 Jun;10(6):105296. doi: 10.1016/j.esmoop.2025.105296. Epub 2025 May 29.
Abstract
摘要
相似文献
1
Letter re: Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting: Are real-world data sufficient to draw a comparison between CDK4/6 inhibitors?关于在美国真实世界环境中CDK4/6抑制剂联合芳香化酶抑制剂治疗HR+/HER2-转移性乳腺癌的总体生存比较的信：真实世界数据是否足以对CDK4/6抑制剂进行比较？
ESMO Open. 2025 Jun;10(6):105296. doi: 10.1016/j.esmoop.2025.105296. Epub 2025 May 29.
2
Response to the letter Re: Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting.对信件《关于：CDK4/6抑制剂联合芳香化酶抑制剂在美国真实世界环境中治疗HR+/HER2-转移性乳腺癌的总生存率比较》的回复
ESMO Open. 2025 Jun 17;10(7):105297. doi: 10.1016/j.esmoop.2025.105297.
3
LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.促黄体生成素释放激素激动剂用于绝经前女性早期乳腺癌的辅助治疗。
Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD004562. doi: 10.1002/14651858.CD004562.pub4.
4
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.来自日本的真实世界证据，涉及接受CDK4/6抑制剂加内分泌治疗作为激素受体阳性、人表皮生长因子受体2阴性晚期或转移性乳腺癌一线或二线治疗的患者的生存结果和治疗顺序。
Breast Cancer. 2025 May 20. doi: 10.1007/s12282-025-01713-7.
5
Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis.低HER2表达对晚期HR + /HER2-乳腺癌患者CDK4/6抑制剂治疗反应的影响：一项多中心真实世界数据分析
Arch Gynecol Obstet. 2025 Feb;311(2):423-427. doi: 10.1007/s00404-024-07761-2. Epub 2024 Oct 7.
6
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.芳香化酶抑制剂用于治疗绝经后妇女的晚期乳腺癌。
Cochrane Database Syst Rev. 2007 Jan 24(1):CD003370. doi: 10.1002/14651858.CD003370.pub2.
7
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
8
Hormonal therapies for early breast cancer: systematic review and economic evaluation.早期乳腺癌的激素疗法：系统评价与经济学评估
Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. doi: 10.3310/hta11260.
9
Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting.CDK4/6 抑制剂对辅助治疗中芳香化酶抑制剂相关肌肉骨骼综合征（AIMSS）的影响。
Breast J. 2023 May 31;2023:3614296. doi: 10.1155/2023/3614296. eCollection 2023.
10
CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis.CDK4/6 抑制剂作为激素受体阳性、HER2 阴性早期乳腺癌的辅助治疗：系统评价和荟萃分析。
ESMO Open. 2021 Apr;6(2):100091. doi: 10.1016/j.esmoop.2021.100091. Epub 2021 Mar 18.
本文引用的文献
1
Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting.美国真实世界中CDK4/6抑制剂联合芳香化酶抑制剂用于HR+/HER2-转移性乳腺癌的总生存比较
ESMO Open. 2025 Jan;10(1):104103. doi: 10.1016/j.esmoop.2024.104103. Epub 2025 Jan 3.
2
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.RIGHT Choice 研究的最终结果：在激素受体阳性/人表皮生长因子受体 2 阴性、临床侵袭性强的绝经前晚期乳腺癌患者中，瑞博西利联合内分泌治疗对比联合化疗的疗效。
J Clin Oncol. 2024 Aug 10;42(23):2812-2821. doi: 10.1200/JCO.24.00144. Epub 2024 May 21.
3
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.阿贝西利联合非甾体芳香化酶抑制剂作为 HR+/HER2-晚期乳腺癌的初始治疗：MONARCH 3 的最终总生存结果。
Ann Oncol. 2024 Aug;35(8):718-727. doi: 10.1016/j.annonc.2024.04.013. Epub 2024 May 8.
4
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.哌柏西利联合来曲唑治疗晚期乳腺癌的总生存期。
J Clin Oncol. 2024 Mar 20;42(9):994-1000. doi: 10.1200/JCO.23.00137. Epub 2024 Jan 22.
5
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.瑞博西林联合来曲唑治疗晚期乳腺癌的总生存期。
N Engl J Med. 2022 Mar 10;386(10):942-950. doi: 10.1056/NEJMoa2114663.
Zotero 插件